Global Discovery Chemistry; ‡Developmental & Molecular Pathways, §Analytical Sciences, Novartis Institutes for BioMedical Research , Basel 4002, Switzerland.
J Med Chem. 2014 Apr 24;57(8):3358-68. doi: 10.1021/jm4019355. Epub 2014 Apr 15.
Oxysterols have recently been identified as natural ligands for a G protein-coupled receptor called EBI2 (aka GPR183) ( Nature 2011 , 475 , 524 ; 519 ). EBI2 is highly expressed in immune cells ( J. Biol. Chem. 2006 , 281 , 13199 ), and its activation has been shown to be critical for the adaptive immune response and has been genetically linked to autoimmune diseases such as type I diabetes ( Nature 2010 , 467 , 460 ). Here we describe the isolation of a potent small molecule antagonist for the EBI2 receptor. First, we identified a small molecule agonist NIBR51 (1), which enabled identification of inhibitors of receptor activation. One antagonist called NIBR127 (2) was used as a starting point for a medicinal chemistry campaign, which yielded NIBR189 (4m). This compound was extensively characterized in binding and various functional signaling assays. Furthermore, we have used 4m to block migration of a monocyte cell line called U937, suggesting a functional role of the oxysterol/EBI2 pathway in these immune cells.
氧化甾醇最近被鉴定为一种称为 EBI2(又名 GPR183)的 G 蛋白偶联受体的天然配体(自然 2011 ,475 ,524 ;519 )。EBI2 在免疫细胞中高度表达(J. Biol. Chem. 2006 ,281 ,13199 ),其激活被证明对适应性免疫反应至关重要,并与自身免疫性疾病(如 1 型糖尿病)有遗传关联(自然 2010 ,467 ,460 )。在这里,我们描述了一种有效的 EBI2 受体小分子拮抗剂的分离。首先,我们鉴定了一种小分子激动剂 NIBR51(1),它能够识别受体激活的抑制剂。一种名为 NIBR127(2)的拮抗剂被用作药物化学研究的起点,产生了 NIBR189(4m)。该化合物在结合和各种功能信号转导测定中进行了广泛的表征。此外,我们使用 4m 阻断单核细胞系 U937 的迁移,这表明氧化甾醇/EBI2 途径在这些免疫细胞中具有功能作用。